The United States of America, As Represented by the Secretary, Department of Health and Human Services

Rxcell Inc.

Amedica Corporation

Life Technologies Corporation

University of Utah Research Foundation

The Government of the United States of America

Eyestem Research Private Limited

Mahendra Rao

Xianmin Zeng

Manfred Boehm

Guibin Chen

Andre Larochelle

Ashok Khandkar

Kyle R Gee

Ramaswamy Lakshminarayanan

Upinder Singh

Kapil Bharti

Darrel S Brodke

Scott Grecian

Uma Lakshmipathy

Rene Quintanilla

Tahmina Mujtaba

Dhruv Sareen

Reena Rathod

Sushma Nanjunda Swamy

Nasir Malik

Vijay Bhaskar Konala Reddy

Raymond Funahashi

Rajarshi Pal

Harshini Surendran

Mohanapriya Rajamoorthy

Jizhong Zou

Yuan Yuan Wu

Ying Liu

Rajani Battu

Deepak Lamba

Methods and compositions for rapid development of reporter lines utilizing safe harbor sites in iPSCS, as well as other progenitor cells, pluripotent and multipotent stem cells and differentiated cells, and multiple Lox sites are provided.

Methods and compositions for rapid generation of single and multiplexed reporters in cells

Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derided cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

Human iPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings

Methods are provided for generating multiple cellular products via differentiation of cells from single clinically compliant pluripotent cells into multiple cellular products selected from retinal epithelium, retinal progenitors, neural stem cells, dopaminergic neurons, astrocytes, hepatocytes, endothelial cells and mesenchymal cells using standard differentiation protocols for the multiple cellular products.

Method for generating multiple cellular products from single pluripotent cell source

A unified cell differentiation protocol for obtaining photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid from pluripotent stem cells is described. Also described are photoreceptor cells, retinal pigmented epithelium, and 3D retinal organoid obtained from pluripotent stem cells. Also described are a pharmaceutical composition and a medicament containing the photoreceptor cells, retinal pigment epithelium, and 3D retinal organoid as described.

Method for producing photoreceptor cells, retinal pigmented epithelial cells, and retinal organoids

Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

Human IPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings

Described herein are recombinant polynucleotide-binding polypeptides, recombinant fusion proteins made with the described polynucleotide-binding polypeptides, methods of using the described recombinant polynucleotide-binding polypeptides and recombinant fusion proteins to modify genomic DNA of cells and, in some embodiments, create recombinant cells. Methods are also provided herein for genetically modifying a neuronal stem cell. Methods are also provided for treating a neurological disorder in a subject that include the administration of genetically modified neuronal stem cells produced by the methods disclosed herein.

Engineering neural stem cells using homologous recombination

The invention relates to novel substrates and methods for staining live stem cells. The stain may be used to identify induced pluripotent stem cell colonies during the process of somatic cell reprogramming.

Substrates and methods for staining live stem cells

An isolated, pure homogeneous population of mammalian astrocyte restricted precursor cells which is CD44 immunoreactive and which generate astrocytes but not oligodendrocytes is provided. Methods for isolating and using these mammalian astrocyte restricted precursor cells are also provided.

Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof

An improved ceramic bone graft is provided for human implantation, particularly such as a spinal fusion cage for implantation into the inter-vertebral space between two adjacent vertebrae. The improved spinal fusion cage includes a substrate block of high strength ceramic having a selected size and shape to fit the anatomical space, and a controlled porosity analogous to natural bone. The substrate block is coated with a bio-active surface coating material such as hydroxyapatite or a calcium phosphate to promote bone ingrowth and enhanced bone fusion. Upon implantation, the fusion cage provides a spacer element having a desired combination of mechanical strength together with osteoconductivity and osteoinductivity to promote bone ingrowth and fusion, as well as radiolucency for facilitated post-operative monitoring. The fusion cage may additionally carry one or more natural or synthetic therapeutic agents for further promoting bone ingrowth and fusion.

Radiolucent bone graft

Radiolucent spinal fusion cage

Growing community of inventors

Timonium, MD, United States of America

Mahendra Rao